Augurix SA produces companion diagnostics devices to facilitate early diagnosis and confirmation of several infectious diseases.
Our products target different application:
• At the primary care, our screening tests allow medical professionals to discriminate serious, organic conditions from functional diseases. They do this directly at the point of care, with the same performance as with a lab test – but cheaper and quicker.
Our products target different application:
• At the primary care, our screening tests allow medical professionals to discriminate serious, organic conditions from functional diseases. They do this directly at the point of care, with the same performance as with a lab test – but cheaper and quicker.
Location: Switzerland, Wallis, Monthey
Employees: 1-10
Total raised: $3.35M
Founded date: 2007
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.01.2014 | - | $3.35M | - |
Mentions in press and media 9
| Date | Title | Description |
| 08.04.2020 | Launch of the first rapid test for COVID-19 on the Swiss market | The rapid test has been co-developed by Augurix and GaDia on the basis of SARS-Cov 1 and on the experience gained during the validation of previous rapid tests such as the detection of infectious and nosocomial diseases or celiac disease, a... |
| 08.04.2020 | Launch of the first rapid test for COVID-19 on the Swiss market | |
| 18.04.2016 | Attraktive Engagements bei Start-ups | |
| 30.09.2015 | BioArk: une nouvelle extension pour les sciences de la vie | |
| 05.05.2014 | Australien market open for Augurix | |
| 28.01.2014 | Augurix raises CHF 3 million | |
| 18.12.2013 | Winning ventures of IMD Startup Competition announced | pryvChosen from over 100 applicants over the past months, find below the names of the companies who will work with IMD’s MBA and EMBA classes in 2014. Augurix Diagnostics (EMBA) Augurix Diagnostics is active in companion diagnostics devices... |
| 21.03.2013 | Augurix, ETHZ and University of Zürich to initiate joint research programme | |
| 15.10.2012 | Augurix: excellent results of new clinical study |